ATE296619T1 - Feste orale dosierungsform von simethicon - Google Patents

Feste orale dosierungsform von simethicon

Info

Publication number
ATE296619T1
ATE296619T1 AT02256741T AT02256741T ATE296619T1 AT E296619 T1 ATE296619 T1 AT E296619T1 AT 02256741 T AT02256741 T AT 02256741T AT 02256741 T AT02256741 T AT 02256741T AT E296619 T1 ATE296619 T1 AT E296619T1
Authority
AT
Austria
Prior art keywords
simethicon
dosage form
oral dosage
solid oral
solid
Prior art date
Application number
AT02256741T
Other languages
German (de)
English (en)
Inventor
Christopher E Szymczak
James T Walter
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Application granted granted Critical
Publication of ATE296619T1 publication Critical patent/ATE296619T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02256741T 2001-09-28 2002-09-27 Feste orale dosierungsform von simethicon ATE296619T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/966,441 US7101573B2 (en) 2001-09-28 2001-09-28 Simethicone solid oral dosage form

Publications (1)

Publication Number Publication Date
ATE296619T1 true ATE296619T1 (de) 2005-06-15

Family

ID=25511414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02256741T ATE296619T1 (de) 2001-09-28 2002-09-27 Feste orale dosierungsform von simethicon

Country Status (18)

Country Link
US (3) US7101573B2 (enExample)
EP (1) EP1297825B1 (enExample)
AR (1) AR036700A1 (enExample)
AT (1) ATE296619T1 (enExample)
AU (1) AU2002301259C1 (enExample)
BR (1) BR0204001A (enExample)
CA (1) CA2405190C (enExample)
CO (1) CO5390073A1 (enExample)
DE (1) DE60204403T2 (enExample)
DK (1) DK1297825T3 (enExample)
ES (1) ES2243664T3 (enExample)
HU (1) HUP0203176A2 (enExample)
MX (1) MXPA02009570A (enExample)
NZ (1) NZ521657A (enExample)
PL (1) PL204141B1 (enExample)
PT (1) PT1297825E (enExample)
RU (1) RU2362569C2 (enExample)
ZA (1) ZA200207755B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
WO2003047551A1 (en) * 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US7179488B2 (en) 2001-11-29 2007-02-20 Bob Sherwood Process for co-spray drying liquid herbal extracts with dry silicified MCC
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
US7341742B2 (en) * 2002-09-30 2008-03-11 L. Perrigo Company Simethicone containing tablet composition and method
EP1563837A1 (en) * 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
UA86802C2 (ru) * 2004-04-13 2009-05-25 Бёрингер Ингельхайм Интернациональ Гмбх Комбинация симетикона и бисакодила для предрасположенных к запору пациентов, которые страдают от ощущения вздутия живота
WO2005105102A1 (en) * 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
US20060024384A1 (en) * 2004-07-29 2006-02-02 Giordano John A Compositions and methods for nutrition supplementation
US20060024409A1 (en) * 2004-07-29 2006-02-02 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
KR20140065482A (ko) * 2005-03-24 2014-05-29 다이이찌 산쿄 가부시키가이샤 의약용 조성물
US20080058282A1 (en) * 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
BRPI0615607A2 (pt) * 2005-08-30 2011-05-24 Lek Pharmaceuticals composição farmacêutica compreendendo perindopril ou seus sais
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US20080015260A1 (en) * 2006-07-13 2008-01-17 Kiel Laboratories, Inc. Pharmaceutical compositions having improved stability and methods for preparation and use
US20080038410A1 (en) * 2006-08-18 2008-02-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
WO2008056200A1 (en) * 2006-11-10 2008-05-15 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of simethicone
MX2009005339A (es) * 2006-11-21 2009-06-01 Mcneil Ppc Inc Suspensiones analgesicas de liberacion modificada.
US9833510B2 (en) * 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE AND BUFFER AGENTS AND METHOD OF USE
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
NZ593831A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
JP5410819B2 (ja) * 2009-04-09 2014-02-05 ライオン株式会社 木クレオソート含有固形製剤
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2012145651A2 (en) 2011-04-21 2012-10-26 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
WO2012170676A1 (en) 2011-06-08 2012-12-13 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
US9370505B2 (en) 2011-09-08 2016-06-21 Mereo Biopharma 2 Limited Pharmaceutical compositions comprising an aromatse inhibitors
IN2014DN03373A (enExample) * 2011-10-27 2015-06-05 Borody Thomas J
ITMI20112221A1 (it) * 2011-12-05 2013-06-06 Altergon Sa Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio
IN2014MN01382A (enExample) 2011-12-14 2015-04-17 Disphar Int Bv
RU2491941C1 (ru) * 2011-12-27 2013-09-10 Вадим Алексеевич Козловский Композиционный энтеросорбент
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
GB201506755D0 (en) 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
MA41620A (fr) 2015-05-14 2018-01-09 Abdi Ibrahim Ilac Sanayi Ve Ticaret A S Composition pharmaceutique comprenant de la siméthicone et de l'otilonium
JP6724537B2 (ja) * 2015-05-26 2020-07-15 大正製薬株式会社 固形製剤
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
EP3294269A1 (en) 2015-06-12 2018-03-21 Santa Farma Ilaç Sanayi A.S. Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
CA3001337C (en) 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
MX385008B (es) * 2016-12-14 2025-03-14 Rhein Siegfried Sa De Cv Composicion mejorada de lansoprazol y simeticona y procesos para prepararla.
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
KR102648960B1 (ko) 2017-09-29 2024-03-20 존슨 앤드 존슨 컨수머 인코포레이티드 고체 시메티콘 입자 및 이의 투여 형태
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
FR3117780B1 (fr) * 2020-12-22 2024-04-05 Oreal Composition anhydre sous forme de poudre compacte comprenant un sel de magnesium et de la cellulose microcristalline
CN116159032A (zh) * 2023-03-31 2023-05-26 成都恒瑞制药有限公司 盐酸西替利嗪片及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
US4744987A (en) * 1985-03-08 1988-05-17 Fmc Corporation Coprocessed microcrystalline cellulose and calcium carbonate composition and its preparation
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5073384A (en) * 1989-10-19 1991-12-17 Valentine Enterprises, Inc. Maltodextrin/defoaming composition combinate
IN171919B (enExample) 1989-11-01 1993-02-06 Mcneil Ppc Inc
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JP3177707B2 (ja) 1991-10-08 2001-06-18 堀井薬品工業株式会社 消化管内ガス除去剤
CA2134467A1 (en) * 1992-04-30 1993-11-11 Donald Johnson Stable hydrated cephalosporin dry powder for oral suspension formulation
GR1002332B (el) * 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
CA2110313C (en) * 1992-12-01 2004-10-26 Edward John Roche Pharmaceutical compositions containing a guanidinothiazole compound and antacids
FR2705966B1 (fr) * 1993-06-04 1995-08-25 Dow Corning Sa Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
EP0725630A1 (en) * 1993-10-28 1996-08-14 The Procter & Gamble Company Fast dissolving dosage forms containing magnesium aluminum silicate and multiple active ingredients
EP0659403B1 (en) 1993-12-15 2001-03-14 National Starch and Chemical Investment Holding Corporation Use of oil adsorbent natural polymer for cosmetic and pharmaceutical applications
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US6106865A (en) * 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
WO1999063969A1 (en) * 1998-06-08 1999-12-16 Groenewoud Pieter J Stabilized thyroxine medications
US6126967A (en) 1998-09-03 2000-10-03 Ascent Pediatrics Extended release acetaminophen particles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form

Also Published As

Publication number Publication date
CO5390073A1 (es) 2004-04-30
US7101573B2 (en) 2006-09-05
RU2002125821A (ru) 2004-03-27
EP1297825A1 (en) 2003-04-02
US20070196468A1 (en) 2007-08-23
ZA200207755B (en) 2004-03-26
AU2002301259B2 (en) 2009-01-22
NZ521657A (en) 2004-05-28
BR0204001A (pt) 2003-09-16
US7691409B2 (en) 2010-04-06
PL204141B1 (pl) 2009-12-31
EP1297825B1 (en) 2005-06-01
US20030091624A1 (en) 2003-05-15
ES2243664T3 (es) 2005-12-01
AR036700A1 (es) 2004-09-29
AU2002301259C1 (en) 2009-07-23
DK1297825T3 (da) 2005-09-26
US20100135982A1 (en) 2010-06-03
RU2362569C2 (ru) 2009-07-27
CA2405190A1 (en) 2003-03-28
DE60204403D1 (de) 2005-07-07
MXPA02009570A (es) 2004-07-30
CA2405190C (en) 2010-11-09
HU0203176D0 (enExample) 2002-11-28
HUP0203176A2 (hu) 2004-07-28
PL356358A1 (en) 2003-04-07
DE60204403T2 (de) 2006-05-04
PT1297825E (pt) 2005-08-31

Similar Documents

Publication Publication Date Title
ATE296619T1 (de) Feste orale dosierungsform von simethicon
ATE289796T1 (de) Orale zusammensetzung
FI20011478A0 (fi) Farmaseuttinen koostumus
IS6686A (is) Hýdrógel-drifið lyfjaskömmtunarform
NO20033384L (no) Farmasoytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
EE200300416A (et) Ravimvorm
ATE353627T1 (de) Stabilisierte orale suspensionsformulierung
NO20040125L (no) Enterale formuleringer
EE05020B1 (et) Glburiidi ravimkoostis
EE200300589A (et) Ravimkoostised
NO20035627D0 (no) Farmasöytisk formulering
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20041383L (no) Flashsmelte oral doseringsformulering
DE60326998D1 (de) Orale zubereitung
NO20041968L (no) Anvendelse av cystationin
NO20040857L (no) Ny oral forlenget frigivelses doseringsform.
NO20033073D0 (no) Farmasöytisk sammensetning inneholdende citalopram
EP1418810A4 (en) TREATMENT OF HEMOPHILIA ORAL
DE60221724D1 (de) Anti-HIV Substanz
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
EP1413314A4 (en) MEDICAL COMPOSITIONS
NO20040866L (no) Ny oral forlenget frigivelses doseringsform
DE60234539D1 (de) Geschmacksmaskierte orale zubereitung von telithromycin
NO20041236L (no) Farmasoytisk formulering

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1297825

Country of ref document: EP

REN Ceased due to non-payment of the annual fee